Intellia Therapeutics Inc
$ 14.95
5.58%
17 Apr - close price
- Market Cap 1,672,771,000 USD
- Current Price $ 14.95
- High / Low $ 15.14 / 14.49
- Stock P/E N/A
- Book Value 5.77
- EPS -3.81
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.54 %
- 52 Week High 28.25
- 52 Week Low 6.83
About
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$25.29
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-20 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-22 | 2023-11-09 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.83 | -0.92 | -0.98 | -1.1 | -1.27 | -1.34 | -1.52 | -1.12 | -1.46 | -1.38 | -1.4 | -1.17 |
| Estimated EPS | -0.96 | -1.01 | -1.03 | -1.2711 | -1.3164 | -1.38 | -1.23 | -1.38 | -1.45 | -1.5 | -1.32 | -1.4 |
| Surprise | 0.13 | 0.09 | 0.05 | 0.1711 | 0.0464 | 0.04 | -0.29 | 0.26 | -0.01 | 0.12 | -0.08 | 0.23 |
| Surprise Percentage | 13.5417% | 8.9109% | 4.8544% | 13.4608% | 3.5248% | 2.8986% | -23.5772% | 18.8406% | -0.6897% | 8% | -6.0606% | 16.4286% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.94 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NTLA
2026-04-17 19:12:07
Intellia Therapeutics (NTLA) has seen recent share price volatility, closing at US$14.16, with mixed short-term returns but strong year-to-date and one-year performance. Despite trading below analyst price targets and a significantly higher intrinsic value according to Simply Wall St's DCF model, the market's current valuation remains a point of interest for investors. The article explores how demographics and genetic conditions support Intellia's value, but highlights risks such as disappointing trial results or payer pushback on costs.
2026-04-10 20:39:16
Intellia Therapeutics, Inc. has amended its bylaws, effective April 7, 2026, to allow shareholders to correct "facially apparent deficiencies" in timely notices for director nominations or other proposals. The company is now required to notify shareholders of such errors. Additionally, the updated bylaws designate U.S. federal district courts as the exclusive forum for complaints under the Securities Act of 1933 or the Securities Exchange Act of 1934, unless Intellia agrees otherwise in writing.
2026-04-09 07:09:20
Intellia Therapeutics (NTLA) has seen a resurgence in investor interest following the FDA's clearance of its MAGNITUDE trials and an analyst upgrade, leading to significant short-term stock gains. Despite trading at a high price-to-sales ratio compared to industry averages, analysts view the stock as undervalued, with a narrative fair value of $25.29 against a current price of $13.55, driven by the expansion of its gene editing programs for conditions like ATTR amyloidosis and HAE. The future valuation, however, significantly depends on successful late-stage trial execution, real-world safety, and navigating competitive and reimbursement challenges.
2026-04-09 05:09:20
Intellia Therapeutics (NTLA) saw a 14.2% stock price increase after the FDA lifted clinical holds on its MAGNITUDE and MAGNITUDE-2 ATTR trials, following a patient death deemed unrelated to the treatment. This regulatory clarity, along with an upgrade from Jones Trading, has bolstered investor confidence in Intellia's CRISPR pipeline despite ongoing losses and competition. The company's investment narrative now focuses on the upcoming HAELO Phase 3 data and potential commercial uptake of its one-time gene therapies.
2026-04-08 09:39:18
Intellia Therapeutics (NTLA) is drawing renewed attention after the FDA lifted clinical holds on its MAGNITUDE trials, following a determination that a patient death was unlikely related to its therapy. The stock has seen recent rebounds, with a 1-year total shareholder return of 115.76%, contrasting a multi-year decline. While analysts view Intellia as significantly undervalued with a fair value of $25.29, its high Price/Sales ratio of 23.7x suggests the market might already be pricing in future growth, indicating mixed signals for investors.
2026-04-06 23:40:29
Intellia Therapeutics (NTLA) shares rose 14.2% after the FDA lifted clinical holds on its MAGNITUDE and MAGNITUDE-2 ATTR trials, providing renewed regulatory clarity. This decision followed an upgrade from Jones Trading and has positively impacted Intellia's investment narrative, particularly concerning its CRISPR pipeline's resilience. The company now looks forward to key HAELO Phase 3 data, reinforcing the potential for its one-time CRISPR interventions, despite ongoing concerns about long-term safety and commercial viability.
